





Burnet
reach for the many

Stellabody® Anti-Shield

A new strategy for tackling treatment-resistant blood cancers



Treatment-resistant tumours survive by building defenses against antibody-mediated immune attack. Stellabody® Anti-Shield turns this defense into a point of vulnerability. It attacks a surviving tumour cell directly while bringing down its protective shield, to restore and amplify complement-mediated killing for potent cancer cell elimination.



Stellabody® technology inserted into the Fc domain exploits natural antibody behaviour to facilitate the formation of hexamers.

This transforms and enhances the action of antibodies and related biologics, transforming them into highly potent complement killing therapeutics.

In-house generated Ramos (R100) refractory cell line



Our lead Stellabody® Anti-Shield candidate breaks through treatment resistance, restoring potent complement-mediated tumour killing where conventional monoclonal antibodies fail, with up to 5-fold greater potency than SB-enabled CD20 standard-of-care.

Protected by a broad, expanding IP estate

Stellabody® is protected by four patent families covering Fc engineering, bispecific antibodies and antibody-like modalities. Anti-Shield builds on this foundation with a differentiated target-led strategy designed to support new, defensible composition-of-matter IP.

Invest with us



Carli Roulston
Head of Commercial Ventures
carli.roulston@burnet.edu.au



Jen Barnes
Director, Commercialisation
and Research Translation
jennifer.barnes@burnet.edu.au

Office address: 85 Commercial Road, Melbourne, Victoria, 3004 ph: + 61 3 9282 2111

 burnet.edu.au